NCT02898662 - AZD1419 Ph2a Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 12, 2016

Primary Completion Date

September 25, 2018

Study Completion Date

September 25, 2018

Conditions

Asthma

Interventions

DRUG

AZD1419

Inhaled AZD1419 administered at the clinic as once weekly inhalations with the I-neb® device. Start dose is 4 mg and dose adaptation is applied (downtitration to 1mg or uptitration to 8 mg or remain on 4 mg) based on appearance of flu like adverse events

DRUG

Placebo

Inhaled Placebo administered at the clinic as once weekly inhalations with the I-neb® device. Start dose is Placebo 4 mg and dose adaptation is applied (downtitration to 1mg or uptitration to 8 mg or remain on 4 mg) based on appearance of flu like adverse events

Trial Locations (15)

2045

Research Site, Törökbálint

2400

Research Site, København NV

2650

Research Site, Hvidovre

2660

Research Site, Balassagyarmat

3529

Research Site, Miskolc

3780

Research Site, Edelény

4700

Research Site, Næstved

5000

Research Site, Odense C

8582

Research Site, Farkasgyepü

80-214

Research Site, Gdansk

90-153

Research Site, Lodz

59-300

Research Site, Lubin

587 58

Research Site, Linköping

221 85

Research Site, Lund

141 86

Research Site, Stockholm